| 石 磊,朱瑞雪,安小翠,叶 峰,贾海娟.胸腺法新联合恩替卡韦治疗慢性病毒性乙型肝炎的疗效及对患者血清HA、Ⅳ-C、LN和免疫功能的影响[J].现代生物医学进展英文版,2019,19(22):4362-4366. |
| 胸腺法新联合恩替卡韦治疗慢性病毒性乙型肝炎的疗效及对患者血清HA、Ⅳ-C、LN和免疫功能的影响 |
| Clinical Efficacy of Thymalfasin Combined with Entecavir inthetreatment of Chronic Viral Hepatitis B and Its Influence on the Serum HA, IV-C, LN Levels and Immune Function |
| Received:June 10, 2019 Revised:June 30, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.22.035 |
| 中文关键词: 慢性病毒性乙型肝炎 胸腺法新 恩替卡韦 肝纤维化 免疫功能 |
| 英文关键词: Chronic viral hepatitis B Thymalfasin Entecavir Hepatic fibrosis Immune function |
| 基金项目:国家自然科学基金项目(81370069)；西安交通大学第一附属医院院基金项目(XJTU1AF-CRF-2015-015) |
| Author Name | Affiliation | E-mail | | SHI Lei | Department of Infectious Diseases the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China | wk9988wkk@163.com | | ZHU Rui-xue | Department of Infectious Diseases the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China | | | AN Xiao-cui | Department of Infectious Diseases the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China | | | YE Feng | Department of Infectious Diseases the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China | | | JIA Hai-juan | Department of Infectious Diseases the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China | |
|
| Hits: 812 |
| Download times: 604 |
| 中文摘要: |
| 摘要 目的：探讨胸腺法新联合恩替卡韦(ETV)治疗慢性病毒性乙型肝炎(CVHB)的临床效果及对患者血清透明质酸(HA)、Ⅳ型胶原(Ⅳ-C)、层黏蛋白(LN)水平和免疫功能的影响。方法：选取我院2013年6月~2016年7月收治的102例CVHB患者，采取随机数字表法均分为两组。对照组(51例)予以恩替卡韦抗病毒治疗，观察组(51例)在此基础上加用胸腺法新治疗。比较两组的临床疗效，治疗前后血清HA、Ⅳ-C、LN水平及外周血T细胞亚群水平的变化和不良反应的发生情况。结果：治疗48周后，观察组总有效率为84.3%，较对照组明显升高(66.7%，P<0.05)。与治疗前相比，两组治疗48周后血清HA、Ⅳ-C、LN水平均显著降低(P<0.01)，外周血CD3+、CD4+、CD4+/CD8+水平较治疗前均显著提高(P<0.01)，且观察组血清HA、Ⅳ-C、LN水平显著低于对照组(P<0.01)。外周血CD3+、CD4+、CD4+/CD8+水平较对照组显著升高(P<0.01)。治疗过程中，对照组和观察组不良反应率分别为7.8%和11.8%，差异无统计学意义(P>0.05)。结论：与单用ETV治疗相比，胸腺法新联合ETV治疗CVHB更能有效消除/缓解患者的症状体征，提高其免疫功能和疗效，且安全性高，可能与其降低血清HA、Ⅳ-C、LN水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical efficacy of thymalfasin combined with entecavir in the treatment of chronic viral hepatitis B and its Influence on the serum HA, IV-C, LN levels and immune function. Methods: 102 cases of patients with CVHB admitted in our hospital from June 2013 to July 2017 were selected and evenly divided into two groups on the basis of random number table. The control group (51 patients) was treated with entecavir, while the observation group (51 patients) was combined with thymalfasin and entecavir. The clinical efficacy, changes of serum HA, Ⅳ-C, LN and peripheral blood T-cell subsets levels before and after treatment, as well as the occurrence of adverse reactions were recorded and compared between the two groups. Results: After 48 weeks of treatment, the overall effective rate of observation group reached 84.3%, which was much higher than that of the control group (P<0.05). Compared with those before treatment, the serum HA, Ⅳ-C, LN levels of both groups after 48 weeks of treatment decreased remarkably (P<0.01), the levels of CD3+, CD4+ and CD4+/CD8+ in peripheral blood were significantly higher than those before treatment (P<0.01), and the levels of serum HA, IV-C and LN in the observation group were significantly lower than those in the control group (P<0.01). The levels of CD3+, CD4+ and CD4+/CD8+ in peripheral blood were significantly higher than those before treatment (P<0.01). During the treatment, the adverse reaction rates of the control group and the observation group were 7.8% and 11.8%, respectively, and the difference was not statistically significant (P>0.05). Conclusion: Compared with ETV alone, thymus combined with ETV treatment of CVHB can effectively eliminate/alleviate the symptoms and signs of patients, improve their immune function and efficacy, and high safety, which may reduce serum HA, IV-C, LN levels. related. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
